One in Three Adults Has This Condition & Most Don’t Know It
If you've ever been told you have a “metabolic risk factor” or “metabolic syndrome” and left the appointment more confused than concerned, you're not alone. Many of my patients come to me with these labels but little context. They’ve heard them in passing from a provider but no one has taken the time to explain what they actually mean or how to respond.
Let’s change that. Because metabolic risk isn’t just medical jargon. It’s your body’s early warning system. And when we understand what it's telling us, we have a powerful opportunity to step in, protect your health, and even reverse disease.
What Is Metabolic Risk?
Metabolic risk refers to the presence of conditions that increase your chances of developing type 2 diabetes, cardiovascular disease, and other complications related to impaired metabolic function. It refers to how well your body manages glucose, cholesterol, blood pressure, and fat distribution.
Some of the most common metabolic risk factors include:
Elevated fasting glucose
Elevated triglycerides
Low HDL cholesterol
Elevated blood pressure
Increased waist circumference or excess visceral fat
These risks tend to cluster together. And when they do, they often point to something deeper going on beneath the surface: a decline in metabolic flexibility and increasing insulin resistance.
Defning Metabolic Syndrome
When three or more metabolic risk factors are present together, it meets the clinical criteria for metabolic syndrome.
Metabolic syndrome is defined as a cluster of interrelated metabolic risk factors that together increase the risk for atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus. The most widely accepted clinical definition, endorsed by an international consortium of cardiovascular and diabetes organizations and adopted by the American College of Cardiology and the American Heart Association, requires the presence of any three of the following five criteria:
Elevated waist circumference (abdominal obesity)
Elevated serum triglycerides (≥150 mg/dL)
Reduced HDL cholesterol (<40 mg/dL in men, <50 mg/dL in women)
Elevated blood pressure (≥130/85 mm Hg or on treatment)
Elevated fasting glucose (≥100 mg/dL or on treatment)
The specific cutoffs may vary slightly depending on the population or guideline, but the core features are consistent across clinical settings. Importantly, metabolic syndrome is not just about an elevated short-term risk of events. It signals a higher long-term risk for both ASCVD and type 2 diabetes.
The Real Culprit: Visceral Fat and Insulin Resistance
The driving force behind metabolic syndrome is often excess visceral adiposity and insulin resistance. Central (abdominal) obesity promotes a chronic low-grade inflammatory state and hormonal disturbances that impair how your cells respond to insulin. Over time, this can lead to hyperglycemia, lipid abnormalities, and hypertension; hallmarks of metabolic dysfunction.
This is why I emphasize body composition over weight or BMI alone in my clinical practice. Two people can have the same body weight and look very different on the inside. It’s the distribution of fat, particularly the fat stored around your organs makes the biggest difference in metabolic risk. We track this using tools like body composition analysis, which provides far more actionable insights than a scale alone.
Why It Matters, even if you feel fine
Here’s the tricky part. Most people with early metabolic dysfunction feel okay. They may have mildly elevated blood pressure or “borderline” labs and are told to just keep an eye on things. But metabolic syndrome is not something to monitor passively. It’s associated with a proinflammatory and prothrombotic state, further increasing cardiovascular risk. The longer these changes are left unaddressed, the more damage they can silently cause.
In fact, the American Heart Association and American College of Cardiology now recognize metabolic syndrome as a risk-enhancing factor for ASCVD and recommend aggressive lifestyle intervention as the foundation of treatment.
There Is a Way Forward
The good news is that metabolic syndrome is both identifiable and modifiable. With the right clinical tools and support, we can lower fasting glucose, reduce visceral fat, improve lipid levels, and ease the burden on the heart and pancreas.
At Well Endocrinology, this begins with a thorough evaluation of your metabolic profile and body composition. From there, we develop a personalized treatment plan that includes evidence-based strategies such as:
Targeted lifestyle interventions focused on sustainable nutrition and physical activity
Pharmacologic therapies when appropriate, including GLP-1 receptor agonists for patients with insulin resistance or obesity
Ongoing support through check-ins that fit your schedule and life
If You’ve Been Told to “Wait and See,” It’s Time to Rethink That
Metabolic risk does not resolve on its own. But with the right attention and action, we can change your trajectory. You don’t need to wait for a diagnosis to take back your health.
If you’ve been told your labs are a little off, if you feel like something isn’t right even though everything “technically” checks out, or if you’ve struggled to get real answers about your weight or energy levels know that there is more to the story. And we’re here to help you write the next chapter.
Schedule a consultation today and take the first step toward metabolic clarity, resilience, and long-term wellness.
References
Grundy SM, Stone NJ, Bailey AL, et al. (2019). 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol, 73(24):e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003
Berglund L, Brunzell JD, Goldberg AC, et al. (2012). Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 97(9):2969–89. https://doi.org/10.1210/jc.2011-3213
Nilsson PM, Tuomilehto J, Rydén L. (2019). The Metabolic Syndrome—What Is It and How Should It Be Managed? Eur J Prev Cardiol, 26(2_suppl):33–46. https://doi.org/10.1177/2047487319886404
Pediatrics. (2011). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, 128(Suppl 5):S213–56. https://doi.org/10.1542/peds.2009-2107C
Whelton PK, Carey RM, Aronow WS, et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol, 71(19):e127–e248. https://doi.org/10.1016/j.jacc.2017.11.006
Whelton PK, Carey RM, Aronow WS, et al. (2018). 2017 ACC/AHA Guideline for High Blood Pressure in Adults. Circulation, 138(17):e484–e594. https://doi.org/10.1161/CIR.0000000000000596
Rosenzweig JL, Bakris GL, Berglund LF, et al. (2019). Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 104(9):3939–3985. https://doi.org/10.1210/jc.2019-01338
Neeland IJ, Lim S, Tchernof A, et al. (2024). Metabolic Syndrome. Nat Rev Dis Primers, 10(1):77. https://doi.org/10.1038/s41572-024-00563-5
